The Mallinckrodt ECP Immunomodulation investigator award

Past Winners

Andrew Fisher, Professor of Respiratory Transplant Medicine at Newcastle University, and Honorary Consultant Respiratory and Transplant Physician at The Newcastle upon Tyne Hospitals NHS Foundation Trust’s Institute of Transplantation.

Andrew Fisher, the project’s principal investigator won this year’s award for a project to help address significa­­nt unmet medical need by evaluating responses to extracorporeal photopheresis therapy (ECP) in chronic lung allograft dysfunction (CLAD).

The study hopes to identify potential novel biomarkers that could guide a precision-medicine approach to ECP treatment, and help people avoid the disability and mortality associated with CLAD – a devastating complication that affects more than half of lung transplant recipients within five years.

See Press Release for more detail.

RIGHT institute (UMR1098) in collaboration with the University Hospital Besançon, France lead by Dr. Etienne Daguindau.

A project that will analyze the immunomodulatory effects of extracorporeal photopheresis therapy (ECP) through innate cells won the  Mallinckrodt plc’s 2021 Advances in Immunomodulatory ECP research award

The winning project, seeks to investigate mechanisms of cell death generated through ECP and the direct effects on the innate cells involved in the resolution of inflammation.

See Press Release for more detail.

Professor David Launay of the University Hospital of Lille in France.

Prof. Launay is based at the Department of Internal Medicine and Clinical Immunology at the University Hospital of Lille, the France-National Reference Center for Systemic and Autoimmune Diseases and part of the European Reference Network ReCONNECT and also works at the Institute for Translational Research in Inflammation (Infinite – U1286 Inserm | Univ. Lille | CHU Lille) in Lille.

The winning entry will evaluate the impact of immunomodulatory intervention on the development of fibrosing processes in an experimental model that could underpin the efficacy of ECP immunomodulation on immune-mediated inflammatory diseases (IMIDs). Among chronic diseases, IMIDs represent a common cause of fibrosis, a hardening or scarring of tissue, and the end result of many chronic inflammatory reactions. Fibrosis carries a high morbi-mortality rate, and a lack of effective therapies to prevent or reverse fibrosis presents a major issue for clinicians.1

See Press Release for more detail.

1. TA Wynn, Cellular and molecular mechanisms of fibrosis, J Pathol 2008; 214: 199–210,, et al.

Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust

The winning entry was submitted by co-investigator Dr. Rachel Crossland of Newcastle University in the United Kingdom.  Collaborators on the winning project include Professor Anne Dickinson, Professor of Marrow Transplant Biology, Newcastle University, Professor Hildegard Greinix, Director of Haematology, Medical University Graz, Graz, Austria; and Dr. Aisling Flinn, Clinical Research Associate in Paediatric Immunology, Newcastle Hospitals NHS Foundation Trust.

Their 12-month study will investigate the impact of ECP Immunomodulation on extracellular vesicles and their profiles in response to therapy in patients with graft-versus-host disease (GvHD). A major complication affecting between 40-70% of Hematopoietic Stem Cell Transplant (HSCT) patients, severe GvHD carries a high mortality rate.1

See Press Release for more detail.

1. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation, Blood. 2012 Jan 5;119(1):296-307. doi: 10.1182/blood-2011-06-364265. Epub 2011 Oct 18.

Dr. Nick Matthews and co-investigator Dr. Arun Alfred of the Department of Haematology at Rotherham NHS Foundation Trust in the United Kingdom.

Their proposal seeks to establish whether immunomodulation achieved through extracorporeal photopheresis (ECP) used in treatment of chronic graft-versus-host disease (GVHD) occurs through mediation of in vivo macrophage activation. Along with the 2018 Investigator Award, the Department of Haematology at Rotherham NHS Foundation Trust will receive an educational grant of €50,000 to support this research. 

See Press Release for more detail.